Civitas Therapeutics has announced that former Sunovion CEO Mark Iwicki will succeed Glenn Batchelder as President and Chief Executive Officer. Iwicki was most recently CEO of Blend Therapeutics. According to Civitas, which is developing inhaled drugs based on its proprietary ARCUS particle manufacturing and delivery platform, Batchelder will continue to serve on the Board of Directors.
Newly appointed Chairman of the Board Timothy Nelson commented, “Having successfully launched numerous products in the pulmonary and central nervous system (CNS) therapeutic areas, Mark is uniquely qualified to direct the advancement of Civitas’ lead program CVT-301, for Parkinson’s disease, into late stage clinical development. Mark’s proven ability to lead high performance teams from early development through commercialization will help achieve the Civitas mission to build a robust and sustainable pipeline around the ARCUS platform. The Board would like to thank Glenn Batchelder for his leadership and contributions to Civitas’ remarkable success to date.”
Iwicki said, “It is a great privilege to join the Civitas team during this pivotal period and fully capitalize on the unique capabilities of the Arcus technology. Civitas unites a highly differentiated and clinically validated platform, a fully-operational commercial manufacturing facility, a lead program addressing a significant unmet need for Parkinson’s patients and an opportunity to produce transformative therapies.”
Read the Civitas Therapeutics press release.
